Blue Water Life Science Advisors, LP reported 10X GENOMICS INC (TXG) in 6 quarterly 13F filings from 2024 Q1 through 2026 Q1. Peak portfolio weight reached 18.56% in 2026 Q1. The latest visible filing shows TXG at 18.56% of the fund.
This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings. Older history is available after unlock; the visible window still shows the most recent pattern.
This page is designed to answer the real investor question behind a 13F filing: how meaningful was Blue Water Life Science Advisors, LP's position in 10X GENOMICS INC, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.
TXG was reported at 18.56% of portfolio in the most recent visible filing.
Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.
Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.
Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.
As of 2026 Q2 — sorted by position size
These are the practical questions this page is built to answer before you even open the full history table.
Blue Water Life Science Advisors, LP reported TXG across 4 quarterly 13F filings, from 2024 Q1 through 2026 Q1.
The largest reported portfolio weight for TXG was 18.56% in 2026 Q1.
The most recent filing on this page is 2026 Q1, when Blue Water Life Science Advisors, LP reported 1,090,000 shares, equal to 18.56% of portfolio, with an estimated market value of $23.1M.
The chart compares Blue Water Life Science Advisors, LP's quarterly TXG portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.
Based on 13F filing dates vs. subsequent TXG price moves, Blue Water Life Science Advisors, LP correctly timed 3 out of 4 reported position changes (75%).